Incidence of Diabetes Following Ramipril or Rosiglitazone Withdrawal

June 2011
Diabetes Care;Jun2011, Vol. 34 Issue 6, p1265
Academic Journal
OBJECTIVE--To examine the impact of withdrawing rosiglitazone and ramipril medication on diabetes incidence after closeout of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. RESEARCH DESIGN AND METHODS--The 3,366 DREAM subjects at trial end who had not developed diabetes while taking double-blind study medication were transferred to single-blind placebo for 2 to 3 months before undergoing an oral glucose tolerance test. Glycemic status was analyzed for the trial plus washout period and for the washout period alone. RESULTS--Following median (interquartile range) 71 (63-86) days drug withdrawal, overall glycemic status remained modestly improved in those allocated ramipril during the trial with an 11% increase in regression to normoglycemia, compared with placebo. In those previously allocated rosiglitazone, glycemic status remained substantially improved with a 49% reduction of new-onset diabetes or death and a 22% increase in regression to normoglycemia, compared with placebo. However, during the washout phase alone the incidence of diabetes or death was identical for those allocated previously to ramipril or placebo, or to rosiglitazone or placebo. CONCLUSIONS--In people allocated to ramipril compared with those not allocated ramipril during the trial, the postwashout normoglycemia incidence was higher. In people allocated to rosiglitazone compared with those not allocated rosiglitazone during the trial, the postwashout incidence of diabetes was significantly lower and the incidence of normoglycemia was higher. During the washout period, diabetes incidence was the same for ramipril versus placebo and for rosiglitazone versus placebo. Rosiglitazone delays disease progression during treatment but the process resumes at the placebo rate when the drug is stopped.


Related Articles

  • Lessons From the Mixed-Meal Tolerance Test. BESSER, RACHEL E. J.; SHIELDS, BEVERLEY M.; CASAS, ROSAURA; HATTERSLEY, ANDREW T.; LUDVIGSSON, JOHNNY // Diabetes Care;Feb2013, Vol. 36 Issue 2, p195 

    OBJECTIVE--Mixed-meal tolerance test (MMTT) area under the curve C-peptide (AUC CP) is the gold-standard measure of endogenous insulin secretion in type 1 diabetes but is intensive and invasive to perform. The 90-minMMTT-stimulated CP ≥0.2 nmol/L (90CP) is related to improved clinical...

  • Bupropion SR worsens mood during marijuana withdrawal in humans. Haney, Margaret; Ward, Amie S.; Comer, Sandra D.; Hart, Carl L.; Foltin, Richard W.; Fischman, Marian W. // Psychopharmacology;2001, Vol. 155 Issue 2, p171 

    Abstract Rationale: Symptoms of withdrawal after daily marijuana smoking include increased ratings of irritability and depression. Similar mood symptoms are reported by cigarette smokers during nicotine abstinence. Objective: Given the successful use of sustained-release bupropion in treating...

  • Effect of high-dose nicotine patch therapy on tobacco withdrawal symptoms among smokeless tobacco users. Ebbert, Jon O.; Dale, Lowell C.; Patten, Christi A.; Croghan, Ivana T.; Schroeder, Darrell R.; Moyer, Thomas P.; Hurt, Richard D. // Nicotine & Tobacco Research;Jan2007, Vol. 9 Issue 1, p43 

    No pharmacotherapies have been shown to increase long-term (≥6-month) abstinence rates among smokeless tobacco (ST) users. Available evidence suggests that underdosing may occur with standard-dose nicotine replacement therapy (NRT) in ST users. We investigated the effect of high-dose...

  • Temporal effects of nicotine nasal spray and gum on nicotine withdrawal symptoms. Hurt, R. D.; Offord, K. P.; Croghan, I. T.; Croghan, G. A.; Gomez-Dahl, L. C.; Wolter, T. D.; Dale, L. C.; Moyer, T. P. // Psychopharmacology;1998, Vol. 140 Issue 1, p98 

    Abstract Nicotine nasal spray and nicotine gum have been found to be effective in relieving nicotine withdrawal symptoms. In this randomized single-blind study, 91 cigarette smokers were randomly assigned to a single 1 mg dose of active nicotine nasal spray (n = 29), active 4 mg nicotine gum (n...

  • Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Haney, Margaret; Hart, Carl L.; Vosburg, Suzanne K.; Comer, Sandra D.; Reed, Stephanie Collins; Foltin, Richard W. // Psychopharmacology;Mar2008, Vol. 197 Issue 1, p157 

    Individuals seeking treatment for their marijuana use rarely achieve sustained abstinence. The objectives of the study are to determine if THC, a cannabinoid agonist, and lofexidine, an α2-adrenergic receptor agonist, given alone and in combination, decreased symptoms of marijuana withdrawal...

  • Alternative approach to the treatment of addictive withdrawal. Gillman, M.A. // South African Journal of Science;Apr96, Vol. 92 Issue 4, p184 

    Reports on the failure of academic departments of psychiatry or provincial hospitals in South Africa to apply or test analgesic nitrous oxide therapy as an alternative approach to the treatment of addictive withdrawal states. Effectiveness of the therapy; Implementation of the therapy at...

  • Venlafaxine withdrawal.  // Reactions Weekly;10/13/2012, Issue 1423, p49 

    The article describes the case of a 46-year-old woman who experienced drug withdrawal syndrome and tinnitus following venlafaxine therapy discontinuation for episodic severe depression.

  • Eculizumab withdrawal.  // Reactions Weekly;8/11/2012, Issue 1414, p24 

    The article describes the case of a woman who developed thrombosis and subsequently died following cessation of eculizumab therapy for paroxysmal nocturnal haemoglobinuria.

  • A new assault on addiction. Cowley, Geoffrey; Archer, Nina // Bulletin with Newsweek;2/7/95, Vol. 116 Issue 5956, p74 

    Reports on the use of the medicine Naltrexone to help alcoholics and drug addicts cope with withdrawal. Marketing of the drug by DuPont Merck Pharmaceutical Co. as Trexan; Renaming it as ReVia; Number of Americans suffering from alcoholism; Warning against heroin and morphine dependents;...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics